Statins could potentially treat dry AMD: study
Statins may have efficacy in treating some patients with dry age-related macular degeneration (AMD), according to data published in the journal EBioMedicine.
Treatment with a high dose of Pfizer's (NYSE: PFE) Lipitor (atorvastatin) showed a clearing up of fatty deposits from the retina and improvements in visual acuity in some patients, according to the study. The data indicates that it may be possible to eventually have a treatment that not only arrests the disease but also reverses its damage and improves the visual acuity in some patients.
About 23 individuals with dry AMD marked by soft lipid deposits were treated with a daily dose of Lipitor of 80mg. In 10 of the patients, clearance of lipid deposits in the retina was observed together with a slight improvement in vision. The researchers noted that it generally took 12 to 18 months of treatment for improvements to manifest.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze